Osaka, Japan-based pharmaceutical firm Shionogi (TYO: 4507) has announced a new project to develop a vaccine for COVID-19, sending shares in the company up over 3% on Monday.
The firm said it was working with public institutions, academia and partner companies to address COVID-19, including in the pursuit of therapeutics, vaccines, and antibody test kits.
A subsidiary of the company, UMN Pharma, is now working on the discovery and development of a recombinant protein vaccine for COVID-19, using their unique Baculovirus Expression Vector System (BEVS) technology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze